Clinical Trial Update: Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma [Phase 2]

View source ↗

Summary

Phase 2 trial updates Nab-sirolimus for recurrent high-grade glioma and newly diagnosed glioblastoma, completion status with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• High Grade Recurrent Glioma

Drugs mentioned

• nab-sirolimus (sirolimus (nanoparticle albumin-bound formulation))

Snippet

Sponsor: Aadi Bioscience, Inc. | Conditions: High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma | Phase 2 | Status: COMPLETED | Results posted: 2023-11-07